Literature DB >> 23948878

Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-analysis.

Andreas Krieg1, Billur Baseras, Monika Tomczak, Pablo Emilio Verde, Nikolas Hendrik Stoecklein, Wolfram Trudo Knoefel.   

Abstract

Survivin has been implicated as a potential prognostic marker in a wide range of malignant tumours. However, the prognostic impact of survivin in gastric cancer remains to be controversial and published data are sometimes heterogeneous. Thus, aim of this study was to review the literature by performing an electronical database search via PubMed and EMBASE to identify eligible studies that assessed the impact of survivin as prognostic marker and its association with clinicopathological variables. Database search until November 21st 2012 retrieved 20 studies comprising 2,695 gastric cancer patients that assessed expression of survivin by immunohistochemistry or RT-PCR analyses in gastric cancer specimens. Meta-analyses of clinicopathological variables revealed an association between the expression of survivin and the presence of lymph node metastases (pooled OR: 0.58; 95 % CI 0.35-0.96). In addition, a correlation between the expression of survivin and overall survival for patients with gastric cancer (pooled HR 1.93; 95 % CI 1.51-2.48) became evident. More importantly, we were able to exclude a severe heterogeneity (I(2) = 31 %) or publication bias for the survival analyses. Furthermore, one-way sensitivity analysis and subgroup analyses regarding the method used to detect survivin, the type of survival analysis, the study quality and whether information was provided regarding neoadjuvant therapy supported our initial results. In conclusion, this meta-analysis indicates the prognostic significance of survivin in patients with gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23948878     DOI: 10.1007/s11033-013-2650-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  49 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

3.  Expression of COX-2, survivin in regional lymph node metastases of gastric carcinoma and the correlation with prognosis.

Authors:  Yong Li; Bi-bo Tan; Li-qiao Fan; Qun Zhao; Yu Liu; Dong Wang
Journal:  Hepatogastroenterology       Date:  2010 Nov-Dec

4.  Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

Authors:  Maria D Begnami; Emy Fukuda; José H T G Fregnani; Suely Nonogaki; André L Montagnini; Wilson L da Costa; Fernando A Soares
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

5.  TFF3 and survivin expressions associate with a lower survival rate in gastric cancer.

Authors:  Jia-Rong Meng; Hui-Zhong Tang; Kai-Zong Zhou; Wu-Hong Shen; He-Yi Guo
Journal:  Clin Exp Med       Date:  2012-09-21       Impact factor: 3.984

6.  Prognostic significance and different properties of survivin splicing variants in gastric cancer.

Authors:  Hua Meng; Caide Lu; Hideaki Mabuchi; Nobuhiko Tanigawa
Journal:  Cancer Lett       Date:  2004-12-28       Impact factor: 8.679

7.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  An anti-apoptosis gene, survivin and telomerase expression in gastric cancer.

Authors:  Akira Tsuburaya; Yoshikazu Noguchi; Takaki Yoshikawa; Aya Saito; Chiharu Doi; Takahide Okamoto; Kuniyasu Fukuzawa
Journal:  Hepatogastroenterology       Date:  2002 Jul-Aug

9.  Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer.

Authors:  Shui Ping Tu; Xiao Hua Jiang; Marie C M Lin; Jian Tao Cui; Yi Yang; Ching Tung Lum; Bing Zou; Yan Bo Zhu; Shi Hu Jiang; Wai Man Wong; Annie On-On Chan; Man Fung Yuen; Shiu Kum Lam; Hsiang Fu Kung; Benjamin Chun-Yu Wong
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

10.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

View more
  17 in total

1.  Survivin and XIAP expression in distinct tumor compartments of surgically resected gastric cancer: XIAP as a prognostic marker in diffuse and mixed type adenocarcinomas.

Authors:  Levent Dizdar; Monika Tomczak; Thomas A Werner; Sami A Safi; Jasmin C Riemer; Pablo E Verde; Nikolas H Stoecklein; Wolfram T Knoefel; Andreas Krieg
Journal:  Oncol Lett       Date:  2017-09-19       Impact factor: 2.967

2.  Clinical and prognostic significance of HIF-1α, PTEN, CD44v6, and survivin for gastric cancer: a meta-analysis.

Authors:  Jing Chen; Tao Li; Qilun Liu; Haiyan Jiao; Wenjun Yang; Xiaoxia Liu; Zhenghao Huo
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

3.  Overexpression of the Survivin gene in SGC7901 cell resistance to cisplatin.

Authors:  Hanzhang Dong; Gaogao Liu; Biao Jiang; Jiubing Guo; Guoquan Tao; Wei Yiu; Jingsong Zhou; Guoxin Li
Journal:  Oncol Lett       Date:  2014-08-20       Impact factor: 2.967

4.  Clinicopathological and prognostic significance of survivin expression in patients with oral squamous cell carcinoma: evidence from a meta-analysis.

Authors:  Shang Xie; Hui Xu; Xiaofeng Shan; Baozhong Liu; Kan Wang; Zhigang Cai
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

5.  Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.

Authors:  Hung Huynh; Richard Ong; Dieter Zopf
Journal:  J Exp Clin Cancer Res       Date:  2015-10-29

6.  CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.

Authors:  Andreas Krieg; Jasmin C Riemer; Leila A Telan; Helmut E Gabbert; Wolfram T Knoefel
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

7.  Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas.

Authors:  Christoph Treese; Pedro Sanchez; Patricia Grabowski; Erika Berg; Hendrik Bläker; Martin Kruschewski; Oliver Haase; Michael Hummel; Severin Daum
Journal:  PLoS One       Date:  2016-12-28       Impact factor: 3.240

8.  Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma.

Authors:  Thomas A Werner; Yasemin Tamkan-Ölcek; Levent Dizdar; Jasmin C Riemer; Achim Wolf; Kenko Cupisti; Pablo E Verde; Wolfram T Knoefel; Andreas Krieg
Journal:  Br J Cancer       Date:  2016-02-04       Impact factor: 7.640

Review 9.  Prognostic Value and Clinicopathological Significance of p-stat3 Among Gastric Carcinoma Patients: A Systematic Review and Meta-Analysis.

Authors:  Kun Ji; Liyan Zhang; Mingxuan Zhang; Qi Chu; Xin Li; Wei Wang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

10.  Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.

Authors:  Xiao Jiao Cheng; Jia Cheng Lin; Yan Fei Ding; Liming Zhu; Jing Ye; Shui Ping Tu
Journal:  Oncotarget       Date:  2016-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.